Stronger Together Global Registry
Evaluating Real-World Spine Outcomes for Spinal and Orthobiologics Products From Around the World
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Colorado
-
Durango, Colorado, United States, 81301
- Spine Colorado
-
-
Ohio
-
New Albany, Ohio, United States, 43054
- OrthoNeuro
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have been treated with at least one SeaSpine product.
- Have obtained radiographic imaging, as part of the standard of care, at the following time points: preoperative and postoperative.
- Have obtained at least one preoperative patient-reported outcome measure, as part of the standard of care.
- Patient is planned, per standard of care, to be assessed with radiographic imaging and consistent patient-reported outcome measure(s) from preoperative through at least two scheduled follow-up visits.
Exclusion Criteria:
- Was not implanted with at least one SeaSpine product during operation
- Any other condition that the Investigator determines is unacceptable for enrollment into this registry
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Implanted with SeaSpine spinal or orthobiologics product
Standard of Care Registry- Patients must have been implanted with at least one SeaSpine product
|
Implanted with SeaSpine spinal or orthobiologic product
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of product failure
Time Frame: 12 months post-operative
|
Product failure is defined as product fracture, loosening, gross migration and/or dissociation.
|
12 months post-operative
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of product-related Serious Adverse Events (SAEs) related to the spine, fusion or bone healing, and intraoperative and postoperative unanticipated adverse device effects
Time Frame: Intra-operative to 24 months
|
Product-related SAEs related to the spine, fusion, or bone will be collected for this outcome measure.
|
Intra-operative to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Frank Vizesi, PhD, SeaSpine Orthopedics Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SS-GR-1902
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.